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Gene therapy has emerged as a powerful and very
plastic tool to regulate biological functions in diseased
tissues with application in virtually all medical fields. An
increasing number of experimental and clinical studies
underline the importance of genes as curative agents in
the future. However, intense research is needed to
evaluate the potential of gene therapy to improve
efficacy and minimise the toxicity of the procedure.
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GENERAL ASPECTS
Gene therapy represents a new and promising
therapeutic modality. The underlying principle is
based on the introduction of genetic material into
cells to generate a curative biological effect.1 2
Gene therapy is not limited to hereditary diseases
but can be used for a broad variety of different
acquired diseases, such as infections, degenera-
tive disorders, and cancer. The most challenging
issues for successful application of gene therapy
to human diseases concern: (1) the choice of the
relevant therapeutic gene, (2) the choice of
promoter and regulatory sequences driving ex-
pression of the transgene; and (3) the vector used
for delivery of the transgene into cells (that is, for
transduction of target cells). Promoter, regulatory
elements, and vector characteristics determine
transduction efficacy (that is, the number of
target cells expressing the transgene and the
intensity of gene expression per cell), specificity
of the transduction, time of transgene expression,
the host’s immune response against the vector,
and eventually undesired side effects. At present,
important efforts are being focused on the search
for vectors with less toxicity and prolonged and
controlled transgene expression, thereby widen-
ing the potential application of gene therapy to a
high spectrum of medical fields.
“In recent years gene therapy has emerged
as a new and promising method to treat
human diseases”
Despite the impressive progress in biomedical
sciences during the last decades, the therapy of
many liver diseases remains unsatisfactory. This
applies not only to primary and metastatic liver
tumours, hepatic cirrhosis, and hereditary meta-
bolic diseases but also to a high proportion of
cases with chronic viral hepatitis that do not
respond to current antiviral therapy. There is evi-
dently an urgent need for efficient alternative
therapeutic approaches and in recent years gene
therapy has emerged as a new and promising
method to treat human diseases.
This article deals with the main features of
gene therapy and focuses on recent gene thera-
peutic strategies for the treatment of viral hepati-
tis and liver cancer.
Genetic material
The genetic material used for gene therapy
embraces both natural and chimeric genes
(which direct the synthesis of therapeutic pro-
teins inside the transduced cells) and also
subgenomic DNA and RNA molecules (which act
directly to modify expression of endogenous
genes). Natural genes are genomic sequences
which encode natural proteins such as enzymes,
cytokines, costimulatory molecules, antigens, sui-
cide genes, and tumour suppressor genes. Chi-
meric genes are genomic constructs that do not
exist in nature which codify for such molecules as
transdominant negative proteins or single chain
antibodies.3
Subgenomic DNA and RNA sequences include
ribozymes, antisense molecules, and RNA decoys,
among others. A ribozyme is an RNA molecule
that hybridises specifically with a messenger RNA
and possesses a catalytic active domain which
cleaves the target mRNA.4 5 Antisense molecules
are DNA or RNA constructs which bind comple-
mentary sequences by hybridisation and interfere
with pre-mRNA processing and messenger RNA
translation and accelerate mRNA degradation.6 7
RNA decoys are RNA sequences which ligate
transactivating proteins as a substitute for their
original binding domain thus blocking the
function of the regulatory proteins.8
Gene therapy vectors
Both viral and non-viral vectors are used to trans-
fer genetic material to the inside of target cells. In
general, non-viral vectors have lower transduc-
tion efficiency and allow for shorter duration of
transgene expression than viral vectors. The ideal
vector should have low antigenic potential, high
capacity, high transduction efficiency, it should
allow controlled and targeted transgene expres-
sion, it should be produced at reasonable expense,
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and it has to be safe for both patient and the environment.
Gene delivery vehicles must be selected according to the spe-
cific therapeutic aim. For some purposes vectors allowing
transient gene expression would be adequate while for other
medical applications long term expression of the transgene is
necessary. In the setting of long term expression, regulation of
the activity of the promoter driving the transgene is frequently
required. The perfect vector covering all therapeutic and safety
requirements does not exist and much work is needed in this
important research field.9
Non-viral vectors
Non-viral vectors bear some advantages with respect to viral
vectors: handling is easier, capacity for DNA sequences is very
high, toxicity is low, they can be specifically targeted to a tis-
sue, and they are not immunogenic thus permitting repeated
vector administration.9 These advantages however are com-
pounded by a relatively low transduction efficiency. Non-viral
vectors include liposomes, DNA-protein complexes, and naked
DNA. The latter can be injected into tissues directly or as DNA
coated gold particles using the gene gun.
Liposomes
This gene transfer system consists of DNA surrounded by a
liposomal coat that allows adsorption to the cell membrane
and penetration inside the cell by endocytosis. The transduc-
tion efficiency of this system is determined by liposome size
and lipid formulation.10 The affinity of liposomes for the target
cells can be modified by incorporating monoclonal antibodies
into the lipid complexes. These vectors are known as
immunoliposomes.11 As DNA can be degraded by lysosomes,
viral proteins can be incorporated into the liposome to elude
the lysosome pathway. These constructs are termed
virosomes12
Particle mediated bombardment or gene gun
DNA coated microparticles (tungsten or gold) are delivered
into cells by devices using gas pressure as the propelling
force.13 Penetration of the microbullets is restricted to superfi-
cial cell layers of the skin or of the treated organ.14
DNA-protein complexes
Hepatocytes express specific membrane receptors, such as the
asialoglycoprotein or the transferrin receptor. These mem-
brane molecules can be used for receptor mediated endocyto-
sis of DNA complexed with the ligand of the receptor.15 Trans-
duction efficacy of this system is limited partly by DNA
degradation due to lysosomal activity.
Naked DNA
Plasmid DNA directly injected into tissues has been shown to
be incorporated by different cell types, such as muscle, skin
cells, and liver cells.16 17 Despite degradation of DNA within a
few days after administration, this technique can be used suc-
cessfully to generate efficient immune responses against the
protein encoded by the injected DNA.
Viral vectors
Viral vectors are the most efficient vehicles for gene transfer.
Different viruses have served to construct gene therapy
vectors, including adenovirus, retrovirus, adeno associated
virus, herpesvirus, lentivirus, baculovirus, SV40 virus, vaccini-
avirus, and others.
“Viral vectors are the most efficient vehicles for gene
transfer”
The list of viral vectors is still expanding and modifications of
already existing systems will widen the list of potential appli-
cations of gene therapy.
Retrovirus
Murine retroviruses are single stranded RNA viruses which
after interaction with a retrovirus receptor can integrate in the
genome of a dividing cell.18 As hepatocytes do not proliferate
actively under physiological conditions, liver tissue is difficult
to transduce with retroviral vectors. Furthermore, transduc-
tion efficacy is limited by the low titre of virus obtained with
the production procedures currently used. As in vitro infection
of hepatocytes leads to higher transduction efficacy, retrovirus
can however be utilised for ex vivo gene transfer.19 20 The recent
development of human lentiviral (human immunodeficiency
virus) based vectors offers promising perspectives for gene
transfer into non-dividing cells.21
Adenovirus
These are double stranded DNA viruses with a natural
tropism for the liver when administrated systemically,22
although liver tropism varies between different species. They
can infect very efficiently both dividing and non-dividing
cells and are easy to produce at high titres.23 Transgenes are
expressed transiently because of the host’s immune response
against viral proteins and the lack of DNA integration into
the host’s genome.24–26 With a first generation adenovirus,
transgene expression is limited to a period of about two
weeks and repetitive systemic administration of adenovirus is
ineffective because of inactivation of the vector by humoral
antibodies. In first generation adenoviruses, the E1 (and E3)
region is deleted rendering it replication defective. Combined
deletion of E1 and E3 results in transgene capacity of up to 8
kb. Second and third generation adenoviruses include
changes in the E2 region or deletion of E4, respectively.
Recently, the so-called gutless adenoviruses have been devel-
oped. These vectors lack all viral sequences except the pack-
aging signals (inverted terminal repeats (ITR)). As a result
they have low toxicity, very high capacity, and do not elicit
immunological responses against the vector, thus allowing
prolonged transgene expression.27 Gutless adenoviruses are
considered to be very promising tools for a number of medi-
cal applications of gene therapy, not only for diseases
concerning the liver but also, because of the low toxicity, for
disorders affecting the central nervous system. Other
research avenues aim to construct tumour specific oncolytic
adenoviruses by modifying the E1A and/or E1B regions of
first generation adenoviruses.28 In this way, conditional repli-
cating adenoviruses can be constructed by placing the E1
gene of the adenoviral genome under the control of a tumour
specific promoter such as AFP promoter. Since AFP expres-
sion (which normally occurs in fetal liver) can be reactivated
in hepatocellular carcinoma (HCC) cells this would restrict
adenovirus replication and the cytopathic effect only to these
tumoral cells.29
Adeno associated virus (AAV)
These are non-pathogenic human parvoviruses which, after
deletion of all viral genes except ITR, have been used with
notorious success as gene therapy vectors. Adeno associated
virus (AAV) vectors can transduce dividing and non-dividing
cells and allow long term transgene expression either by
integration into the host genome or by persistence in the cells
in an episomal form.30 After systemic injection, AAV demon-
strates significant liver tropism. It has been shown that AAV
mediated gene transfer of factor IX to mouse liver induces
persistent curative levels of active factor IX.31 Adjuvant treat-
ment with genotoxic agents (such as gamma irradiation)
enhance expression of the AAV transgene both in vitro and in
vivo.32–34 AAV based vectors, as indicated for gutless adenovi-
ruses, have considerable potential in the therapy of central
nervous system disorders and also in diseases affecting mus-
cle, a cell type that is readily transduced by this type of vector.
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Herpes simplex virus (HSV)
Herpes simplex virus (HSV) is a promising vector for gene
transfer, especially to the nervous system, because of its char-
acteristic neurotropism. Additionally, HSV transduces effec-
tively murine liver tissue in vivo.35
GENE THERAPY FOR LIVER DISEASES
The possibility of transferring functional genes to liver cells
creates an entirely new horizon in the therapy of liver diseases
that will undoubtedly be explored intensely in the coming
years. In this review we will focus on experimental data relat-
ing to gene therapy of viral hepatitis and of primary and
metastatic liver cancer.
Gene therapy for viral hepatitis B and C
Less than 40% of patients with chronic hepatitis B and less
than 20–30% of patients with chronic hepatitis C (results vary
according to viral genotype and viral load) can be treated suc-
cessfully by administration of interferon α (IFN-α). The com-
bination of IFN-α and ribavirin increases the response rate in
patients infected with genotype 136 but no more than 40% of
patients respond to this therapy. It has recently been shown
that pegylated IFN-α generates sustained levels of IFN-α in
blood with a weekly dosage of the drug. This pharmacological
formulation results in a higher response rate (almost 40% of
cases) than with conventional interferon therapy.37 Despite
these improvements, a high percentage of patients with
chronic hepatitis C are still resistant to existing antiviral
therapies.
Gene transfer of IFN-α to the liver using a long term
expression vector could induce prolonged and continuous
IFN-α production by the proper diseased liver. One prelimi-
nary experimental study has recently demonstrated that
administration of an adenovirus expressing IFN-α was effec-
tive in the prevention of viral hepatitis in a mouse model.38
There is a need for testing the therapeutic efficacy and toxicity
of IFN-α gene transfer to the liver using appropriate long term
expression vectors in animal models of chronic viral hepatitis
(such as in the woodchuck model) .
Antisense DNA/RNA or ribozymes are therapeutic mol-
ecules that can also be used to treat viral hepatitis.39 40 By con-
veying these molecules in long term expression vectors capa-
ble of integration into the host genome, a certain proportion of
hepatocytes (and their progeny) would be rendered resistant
to viral infection. As these cells may enjoy a biological advan-
tage over infected cells, it is hoped that replacement of dead
hepatocytes might take place preferentially by the transduced
cells which finally may repopulate the entire liver. These
assumptions should be tested in the future in experimental
animal models.
Gene therapy can also be used to induce prophylactic or
therapeutic antiviral immunity. Injection of naked DNA or of
vectors, such as Semliki Forest virus vectors containing viral
genes, has been shown to be an efficient system to induce pro-
tective antiviral immune responses.41 Administration of genes
coding for viral antigens can be combined with genes encod-
ing immunostimulating molecules such as interleukin (IL)-2,
IL-12, or granulocyte macrophage-colony stimulating factor
(GM-CSF).42 43 Recently, we have shown that the combined
administration of an adenovirus containing the core and E1
sequences from hepatitis C virus (AdCE1) and another one
containing the genes of IL-12 (AdIL-12) resulted in the
generation of a cellular TH1 immune response which was
more intense than that obtained after injection of AdCE1
alone.44 45 In a recent work we found that gene gun bombard-
ment with DNA containing the nucleocapsid of woodchuck
hepatitis virus (WHV) induced a TH2 type of response which
did not protect against a posterior injection of the virus. How-
ever, when a plasmid containing WHV core gene was given
together with another plasmid coding for woodchuck IL-12, T
cell immunity was of the TH1 type and was strongly protective
against viral inoculation.46 Thus combined vaccination with
both viral and cytokine genes may be a promising immunisa-
tion method allowing the induction of a desired pattern of T
cell immunity.
GENE THERAPY FOR NEOPLASTIC LIVER DISEASES
Malignant diseases of the liver rank fifth among all primary
neoplastic diseases.47 48 HCC is the most common primary liver
malignancy with a rising incidence worldwide.47–49 In addition
to primary tumours, the liver is the most common organ
where tumour metastases occur.49 50 Both unresectable HCC
and liver metastases of digestive tumours lack effective
therapy47 48 51 and new therapeutic modalities are urgently
needed.
Transfer of therapeutic genes to the tumour mass or to the
peritumoral tissue provides a promising new approach for
cancer therapy.52–54 In animals, different anticancer gene
therapy strategies have shown promise, including (a) transfer
of tumour suppressor genes (for example, wild-type p53), (b)
antisense strategies aimed at inhibiting oncogene expression,
(c) transduction of tumour cells with suicide genes (such as
HSV-thymidine kinase (HSV-tk)), to sensitise cells to specific
compounds (ganciclovir in the case of HSV-tk), (d) genetic
immunotherapy to stimulate the host’s antitumoral immune
response using immunostimulatory cytokines, chemokines,
costimulatory molecules, combination of cytokines and
chemokines, or genetic vaccination with tumoral antigens,
and (d) transfer of genes which interfere with the biological
programme of tumour growth (for example, antiangiogenic
substances).
“Transfer of therapeutic genes to the tumour mass or to
the peritumoral tissue provides a promising new
approach for cancer therapy”
In the following paragraphs we will concentrate mainly on
suicide genes and genetic immunotherapy.
Drug sensitisation (suicide genes)
This therapy is based on the transfer of a gene encoding a for-
eign enzyme which converts a non-toxic prodrug into a lethal
drug compound.HSV-tk is the best characterised suicide gene.
Expression of functional enzyme HSV-tk in transduced
(tumour) cells induces conversion of the non-toxic prodrug
ganciclovir into a toxic phosphorylated compound which ter-
minates DNA synthesis and inhibits DNA polymerase.55 A
characteristic trait of the suicide genes is the so-called
bystander effect caused by diffusion of the toxic drug metabo-
lite from the transduced cells to the surrounding tissue thus
increasing the number of tumoral cells destroyed by the pro-
cedure. Because of this effect, significant tumour regression
can be achieved even when only a limited percentage of neo-
plastic cells has been transduced.56 57 The bystander effect also
derives from necrosis of tumoral tissue which induces local
inflammation, attraction of dendritic cells, and stimulation of
antitumoral immunity. Thus a synergistic antitumoral effect
has been observed between suicide gene based therapy and
gene transfer of immunostimulatory molecules.58
Several studies have demonstrated the efficacy of the
HSV-tk/ganciclovir system for the treatment of HCC56 59 60 and
metastatic colorectal cancer.61 62 One of the main obstacles
limiting the application of this therapy is related to toxic side
effects affecting non-tumoral tissue.60 63 These side effects can
be reduced by injecting the vector locally inside the tumour or
by the use of tumour specific promoters (such as AFP
promoter for HCC) to limit HSV-tk expression to tumour
tissue.64
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Genetic immunotherapy
The host’s immunity frequently fails to eliminate malignant
tumour tissue either due to the lack of recognisable tumour
antigens or to the inability of tumour antigens to stimulate an
effective immune response.65 66 Defective antitumour immunity
can be attributed partly to the lack of expression of MHC mol-
ecules by tumour cells and also to secretion of immunosup-
pressive factors (such as transforming growth factor β or vas-
cular endothelial growth factor) by the tumour.65 Gene transfer
of cytokines which are important in the regulation of the
immune system can overcome the immune tolerance against
tumoral antigens thus facilitating tumour rejection. Different
cytokines (IL-2, IL-4, IL-6, IL-7; IL-12, INF-γ, tumour necrosis
factor α, GM-CSF) have been used to modulate the host’s
immune response by either ex vivo or in vivo gene transfer.67–70
IL-12 is among the most potent cytokines at stimulating anti-
tumour immunity. IL-12 acts by (a) induction of a TH1 type of
response, (b) activation of natural killer cells and cytotoxic T
lymphocytes, (c) enhanced expression of adhesion molecules
on endothelial cells thus facilitating the traffic of lymphocytes
to the tumour, and (d) induction of a potent antiangiogenic
effect.
In an orthotopic HCC model in Buffalo rats, we have shown
that intratumoral administration of recombinant adenovirus
encoding IL-12 (AdIL-12) caused complete tumour eradication
in most animals and increased long term survival.70 Interest-
ingly, when two tumours were implanted in the same liver,
treatment of only one resulted in regression of both. This effect
has been attributed to the fact that a proportion of the
adenovirus injected into a neoplastic nodule escapes to the gen-
eral circulation and (because of the strong adenoviral hepa-
totropism) infects the whole liver. The IL-12 produced by the
tumour and by hepatocytes surrounding the neoplastic nodules
strongly activates natural killer cells, induces specific anti-
tumoral immunity and enhanced expression of adhesion
molecules in the tumoral vessels, and displays a powerful
antiangiogenic effect with resulting tumour regression.70
AdIL-12 given by the intrahepatic arterial route has also been
shown to be efficient in the treatment of a very aggressivemodel
of multifocal HCC in rats (DENA induced HCC) causing a
significant reduction in tumour burden and prolongation of
survival.70 AdIL-12 was also found to induce potent antitumoral
effects in animal models of metastatic colon cancer model.71
Although IL-12 is a potent antitumoral substance, its use is
also liable to cause systemic toxic effects mainly derived from
the ability of this cytokine to induce IFN-γ production. In
order to enhance the antitumoral activity of IL-12 while
reducing the risk of toxicity, we have tested the therapeutic
effect of a suboptimal dose of AdIL-12 in combination with an
adenovirus expressing the chemokine IP-10 (AdIP-10). The
rationale was to attract immunoeffector cells to the neoplasm
through IP-10 and to activate the attracted lymphocytes with
IL-12. We found that this combined therapy allows reduction
of the dose of AdIL-12 without loss of antitumoral efficacy but
with less risk of toxicity.72 As activation of dendritic cells, the
most efficient antigen presenting cells, is critical for induction
of antitumoral immunity, another possible way to enhance the
antitumoral effect of low doses of IL-12 is to infect dendritic
cells with AdIL-12 ex vivo and to inject these engineered den-
dritic cells into the tumour.73 In animal models of colon cancer
this strategy has proved to be extremely potent at eliminating
tumoral lesions and at eliciting antitumoral immune re-
sponses.
Stimulation of dendritic cells is widely dependent on
activation by costimulatory molecules such as B7 and CD40
ligand (CD40L).74 75 We observed that adenovirus mediated
gene transfer of CD40L (AdCD40L) completely abolished the
tumorigenicity of ex vivo infected rat HCC cells and that
intratumoral injection of AdCD40L into established intra-
hepatic HCC tumour nodules in rats resulted in tumour
regression and prolongation of survival. Treatment of rat HCC
with AdCD40L induced protective antitumour immunity and
was devoid of significant toxicity.75
Genetic vaccination has also been reported to prevent
tumour growth. In a murine model of subcutaneous HCC it
has been shown that DNA vaccination with a cDNA encoding
murine AFP induced tumour regression and prolonged animal
survival. The antitumoral effect was mediated by cytotoxic T
cells, and protective antitumoral immunity was shown to
depend on both CD4+ and CD8+ T cells.76
“Genetic vaccination has also been reported to prevent
tumour growth”
Recently, improved immunisation protocols alternating DNA
priming and recombinant vaccinia Ankara booster generated a
manifold higher immune response than any of these
strategies alone.77 However, these concepts have not yet been
applied in the induction of antitumoral immunity for HCC
treatment.
Some of these anticancer strategies, such as hepatic arterial
administration of adenovirus with wild-type p5378 or intra-
tumoral injection of adenoviral vectors encoding suicide gene
HSV/tk or IL-12 have been applied, or are at present been
tested, in HCC patients in phase I/II clinical trials.
OUTLOOK
Gene therapy has emerged as a powerful and very plastic tool
to regulate biological functions in diseased tissues with appli-
cation in practically all medical fields. An increasing number
of experimental and clinical studies clearly underline the
important role of genes to serve as a curative drug in the
future. However, intense research is needed to evaluate the
potential of gene therapy, to improve efficacy, and to minimise
the toxicity of the procedure.
“Genes can be transferred to tissues and the transferred
gene is functional in vivo”
Future efforts should be directed towards: (1) development of
vectors with high transduction efficiency, high transgene
capacity, and acceptable toxicity profile, (2) development of
systems allowing desired duration and regulation of gene
expression, (3) identification of the ideal therapeutic gene or
gene combinations for each therapeutic indication, (4) testing
of different routes for vector administration, and (5) develop-
ment of innovative methods for large scale industrial produc-
tion to allow accessible costs for wide access to these new
drugs. Intensive testing in animal models to ensure drug
safety and functionality is needed before contemplating clini-
cal applications. On the other hand, carefully designed clinical
trials, under strict regulatory conditions, can provide very
useful information on the potential of gene therapy in
humans, especially in devastating diseases lacking effective
therapy, as is the case for non-resectable chemoresistant
tumours. New imaging techniques such as positron emission
tomography have the potential of detecting and quantitating
the function of the transferred gene to the tissues in vivo, thus
providing a powerful tool to guide the progress of clinical gene
therapy. In summary, genes can be transferred to tissues and
the transferred gene is functional in vivo; this opens a new
field of medical applications which is just beginning.
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